RxDoctor Payments Data

Siavash Karimian, MD

Family Medicine · Palm Desert, CANPI 1437288073

Payments from drug & device makers

$1,690in general payments, 2019–2025

Across 91 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$341
  • Pfizer$264
  • Novartis$226
  • GSK$163
  • Novo Nordisk$121
  • Xeris Pharmaceuticals, Inc.$117
  • plus $457 from 11 others

What the payments were for

  • Food & beverage$1,685100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,690 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$227,924
Medicare patients
341
Services billed
3,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol149$205,914
TrulicityDulaglutide93$103,069
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$65,524
EliquisApixaban122$62,769
JanuviaSitagliptin Phosphate74$41,503
JardianceEmpagliflozin30$40,345
XareltoRivaroxaban56$35,390
LinzessLinaclotide43$25,035
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$19,328
OzempicSemaglutide17$15,861
MyrbetriqMirabegron13$14,515
SantylCollagenase Clostridium Hist.43$13,825
MounjaroTirzepatide13$13,519
Lantus SolostarInsulin Glargine,hum.Rec.Anlog98$12,219
EntrestoSacubitril/Valsartan35$12,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$341$225,243173 claims
Lilly USA, LLCTrulicity, Mounjaro$71$116,587106 claims
GSKTrelegy Ellipta$163$65,52497 claims
PfizerEliquis$264$62,769122 claims
MerckJanuvia$14$41,50374 claims
Boehringer IngelheimJardiance$100$40,34530 claims
AbbVieLinzess$27$25,03543 claims
Novo NordiskOzempic$121$15,86117 claims
Astellas Pharma US IncMyrbetriq$99$14,51513 claims
NovartisEntresto$226$12,01035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Palm Desert

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →